today. yet a you to quarter Thank are another I'm start pleased had to that you, Thank report Good Mitch. everyone. strong XXXX. off for and in productive we very joining afternoon, us
biggest approval. our potential candidate, product date, milestone while one in month, for approaching nearing PDUFA first U.S. the inebilizumab regulatory about company date our to With lead our
company, or spectrum our patients would our moment of optica a be thousands would be course more While victory disorder, importantly, for NMOSD. pivotal for neuromyelitis this of by the it affected
common we progress from make this so, trial you solid parallel launch we ongoing announced our and IIb incredible, results initiated of interim and for Phase affecting a may ago, there us activities, energy pipeline. today. various In all VIBXXXX, trial recently, currently to of of disease VIBXXXX Ib over a for treatment entire approved with rheumatic COVID-XX teams continue our which as a promising have syndrome, our despite patients of is of which Sjogren's no disease seen afternoon, Most to we therapies. the are modifying across pandemic, Phase the are month just The resourcefulness
moved we their to take address into patients and and quickly help and first our but us Thanks who and directly like with can would grateful. impacted. I thousands foremost, are families moment of pandemic, response all patients thoughts been workers to safe our extent we have the that to and keep healthcare to to To contain complete the a the in helping implementing external our flattening nimble the we the of At home virtual a successfully continue from we stakeholder transitioning our the curve, to of to virus employees the the spread and policy engagements. decision-making. serve, work the outbreak, outset be protect support [indiscernible]
effects operations. and we this is tell minimal be, pandemic on still business our will impactful how present, early experienced have been to fortunately it While ultimately too at
supply have clinical trials. drug We to our sufficient and product of launch continue to supply ongoing our
clinical with our enrollments new of of paused trial investigators trials the to However, that in patients we voluntarily some health patient's order our prioritize have of and at sites.
monitor and and federal local this we'll health and weeks to follow coming continue the authorities. from months, to guidance carefully situation Over
XXXX and pathways COVID-XX present have which and range ability pandemic, pursues adjustment on co-stimulatory day-to-day multiple our disease. some of to a our create product our our is three success We distinct R&D devastated by autoantibody, pathways, that approach, autoimmune pipeline in beyond. more signaling to well believe disorders. the that At for operations Despite we're focused make underlie [indiscernible] candidates innate precise cytokine within positioned a
research to our for and study develop Additionally, molecules group new continues pathways.
will brief Here, I history.
We a have development, have of robust built which clinic. in today in three and pipeline five molecules are
autoantibodies XX,XXX is Our potential States the We United and leading and a the neuroinflammatory water that plasma about central the cells severe of are binding bind channel affects cord nerve, primarily system autoantibodies to near These nervous of is believed damage central patients course The a of the to term XX% NMOSD, alone. aquaporin-X. that inebilizumab of attacks, to know protein about trigger plasmablasts produced FDA autoantibodies cells optimal nervous approval patients the spinal system. in disease, milestone NMOSD that which to have and brain. rare and by called astrocytes aquaporin-X in
decline will and attack. In with limiting patients one crucial are to worsening significantly many and Our of attack. disability to subsequent the and quality progressive each the can life is with disability disease. a irreversible devastating attacks come patient's just future time, experience health on patient and This blindness health. paralysis of Preventing
plasmablasts demonstrated our recall, reduction some attack based which new first-line on the of safety momentum you a and worsening pivotal may significant efficacy to As NMOSD from and has CDXX potential results to lesion trial deplete target expressing inebilizumab plasma designed inebilizumab B-cells NMOSD-related patients. include strong and and believe in as We reduction well that we which disability, monotherapy for as reductions be and in reduction hospitalizations. cells MRI a
Results into given has years The with Our duration for two term. attack work years. is insights with treatment some consistent inebilizumab the the analysis of might on patients to free. are up patients of XX% five open-label period and of main extension how remain over long that us inebilizumab primary
long-term inebilizumab. are we the potential by encouraged of So highly benefits
more will about launch would call the Bill? who to I over strategy that, hand our of provide With details to Head our and Ragatz, Commercial, like the Bill readiness.
